NASDAQ: AEMDAethlon Medical Inc Stock
$2.83-0.10 (-3.41%)
Updated Aug 14, 2026
AEMD Price
$2.83
Fair Value Price
$6.96
Market Cap
$2.01M
52 Week Low
$2.63
52 Week High
$137.00
P/E
-0.09x
P/B
0.39x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$6.94M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.2
Operating Cash Flow
-$7M
Beta
1.05
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
AEMD Overview
Aethlon Medical, Inc. operates as a medical technology enterprise, dedicated to innovating solutions for the diagnosis and treatment of life-threatening and organ-jeopardizing diseases within the United States. Central to its pipeline is the Aethlon Hemopurifier, a clinical-stage immunotherapeutic device. This device is engineered to clear the human circulatory system of detrimental tumor-derived exosomes and perilous viruses. Notably, this capability extends to targeting the COVID-19 virus, its various strains, and associated exosomes. Furthermore, Aethlon Medical maintains a collaborative partnership with the University of Pittsburgh Medical Center's Hillman Cancer Center, conducting studies pertinent to head and neck cancer. Established in 1999, the company is headquartered in San Diego, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine AEMD's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
AEMD
Ranked#86 of 98
Ranked#86 of 98
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $41.22 | A | |
| $21.50 | A | |
| $82.22 | A |
Be the first to know about important AEMD news, forecast changes, insider trades & much more!
AEMD News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how AEMD scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
AEMD ($2.83) is undervalued by 59.33% relative to our estimate of its Fair Value price of $6.96 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
AEMD ($2.83) is significantly undervalued by 59.33% relative to our estimate of its Fair Value price of $6.96 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
AEMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more AEMD due diligence checks available for Premium users.
Valuation
AEMD fair value
Fair Value of AEMD stock based on Discounted Cash Flow (DCF)
Price
$2.83
Fair Value
$6.96
Undervalued by
59.33%
AEMD ($2.83) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
AEMD ($2.83) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
AEMD is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
AEMD price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.09x
Industry
24.1x
Market
15.97x
AEMD price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.39x
Industry
3.36x
AEMD is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
AEMD's financial health
Profit margin
Revenue
$0.0
Net Income
-$1.5M
Profit Margin
0%
AEMD's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$6.2M
Liabilities
$1.0M
Debt to equity
0.2
AEMD's short-term assets ($5.61M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
AEMD's short-term assets ($5.61M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
AEMD's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
AEMD's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.9M
Investing
-$9.2k
Financing
$1.8M
AEMD's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
AEMD vs Medical Device Stocks
Aethlon Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.